NO773839L - Fremgangsmaate for fremstilling av ergot-peptid alkaloidpreparatform, egnet for nasal eller pulmonaer tilfoersel - Google Patents
Fremgangsmaate for fremstilling av ergot-peptid alkaloidpreparatform, egnet for nasal eller pulmonaer tilfoerselInfo
- Publication number
- NO773839L NO773839L NO77773839A NO773839A NO773839L NO 773839 L NO773839 L NO 773839L NO 77773839 A NO77773839 A NO 77773839A NO 773839 A NO773839 A NO 773839A NO 773839 L NO773839 L NO 773839L
- Authority
- NO
- Norway
- Prior art keywords
- nasal
- hydrogen
- preparation
- ergot
- active agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- 229930013930 alkaloid Natural products 0.000 title claims description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 19
- 230000002685 pulmonary effect Effects 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 239000013543 active substance Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000000443 aerosol Substances 0.000 description 13
- 239000003380 propellant Substances 0.000 description 12
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 11
- 229960004704 dihydroergotamine Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000007789 gas Substances 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- -1 "Nipakombin" Chemical compound 0.000 description 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 5
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 4
- 229960002802 bromocriptine Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 2
- QKMRPKVJXKAXHL-OLNIQZLRSA-N dihydroergonine Chemical compound C([C@H]1[C@]2(O)O3)CCN1C(=O)[C@H](C(C)C)N2C(=O)[C@]3(CC)NC(=O)[C@H]1CN(C)[C@H](CC=2C3=C4C=CC=C3NC=2)[C@@H]4C1 QKMRPKVJXKAXHL-OLNIQZLRSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940098458 powder spray Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940029284 trichlorofluoromethane Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 description 1
- 229960004290 dihydroergocornine Drugs 0.000 description 1
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 description 1
- 229960004318 dihydroergocristine Drugs 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
- ADYPXRFPBQGGAH-WVVAGBSPSA-N dihydroergotoxine Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-WVVAGBSPSA-N 0.000 description 1
- 229940120500 dihydroergotoxine Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01D—MEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
- G01D2207/00—Indexing scheme relating to details of indicating measuring values
- G01D2207/10—Displays which are primarily used in aircraft or display aircraft-specific information
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1457576 | 1976-11-19 | ||
| CH698977 | 1977-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO773839L true NO773839L (no) | 1978-05-22 |
Family
ID=25700540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO77773839A NO773839L (no) | 1976-11-19 | 1977-11-10 | Fremgangsmaate for fremstilling av ergot-peptid alkaloidpreparatform, egnet for nasal eller pulmonaer tilfoersel |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US4462983A (da) |
| JP (1) | JPS5366440A (da) |
| AT (1) | AT368881B (da) |
| AU (1) | AU520754B2 (da) |
| CA (1) | CA1103585A (da) |
| CS (2) | CS228523B2 (da) |
| CY (1) | CY1266A (da) |
| DE (2) | DE2750090A1 (da) |
| DK (1) | DK153440C (da) |
| ES (1) | ES464275A1 (da) |
| FI (1) | FI773376A (da) |
| FR (1) | FR2371454A1 (da) |
| GB (1) | GB1592563A (da) |
| GR (1) | GR65229B (da) |
| HK (1) | HK85984A (da) |
| HU (1) | HU185924B (da) |
| IE (1) | IE46167B1 (da) |
| IL (1) | IL53419A (da) |
| KE (1) | KE3453A (da) |
| MY (1) | MY8400055A (da) |
| NL (1) | NL187892C (da) |
| NO (1) | NO773839L (da) |
| NZ (1) | NZ185711A (da) |
| PH (1) | PH23643A (da) |
| PT (1) | PT67292B (da) |
| SE (1) | SE451944B (da) |
| SG (1) | SG61784G (da) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2750090A1 (de) * | 1976-11-19 | 1978-06-01 | Sandoz Ag | Neue verabreichungsformen fuer organische verbindungen |
| US4284648A (en) * | 1979-08-03 | 1981-08-18 | The University Of Kentucky Research Foundation | Nasal administration of propranolol |
| CH649300A5 (de) * | 1981-08-07 | 1985-05-15 | Sandoz Ag | Ergopeptinderivate, ihre herstellung und verwendung. |
| FI81258C (fi) * | 1982-02-01 | 1990-10-10 | Sandoz Ag | Foerfarande foer framstaellning av en farmaceutisk komposition foer nasal administration. |
| GB8301659D0 (en) * | 1983-01-21 | 1983-02-23 | Leo Ab | Smoking substitutes |
| GB8413795D0 (en) * | 1984-05-30 | 1984-07-04 | Sandoz Ltd | Organic compounds |
| GB8426922D0 (en) * | 1984-10-24 | 1984-11-28 | Sandoz Ltd | Galenic formulation |
| GB8501015D0 (en) * | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| FR2628638B1 (fr) * | 1985-03-06 | 1992-12-18 | Sandoz Lab | Dispositif de pulverisation par voie nasale d'une dose unitaire de medicament en solution |
| JPS61263918A (ja) * | 1985-05-16 | 1986-11-21 | Banyu Pharmaceut Co Ltd | 経皮吸収用製剤 |
| ATE78158T1 (de) * | 1985-05-22 | 1992-08-15 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| CA1291036C (en) * | 1986-04-23 | 1991-10-22 | Edwin I. Stoltz | Nasal administration of drugs |
| US4782047A (en) * | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
| US4897256A (en) * | 1986-11-25 | 1990-01-30 | Abbott Laboratories | LHRH analog formulations |
| DE3710216A1 (de) * | 1987-03-27 | 1988-10-06 | Rentschler Arzneimittel | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
| GB2216794B (en) * | 1988-03-22 | 1991-11-20 | Fisons Plc | Pharmaceuticals compositions |
| US4929640A (en) * | 1988-04-04 | 1990-05-29 | George D. McAdory | Medicaments intended for combined use in the improvement of lymphocyte function |
| GB2237510B (en) * | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
| IT1247472B (it) * | 1991-05-31 | 1994-12-17 | Fidia Spa | Processo per la preparazione di microsfere contenenti componenti biologicamente attivi. |
| ES2177544T3 (es) * | 1992-06-12 | 2002-12-16 | Teijin Ltd | Polvo ultrafinno para inhalar y metodo para su preparacion. |
| DE69330672T2 (de) * | 1992-06-12 | 2002-06-27 | Teijin Ltd | Pharmazeutische zubereitung zur anwendung in den atemwegen |
| ATE290864T1 (de) * | 1993-03-26 | 2005-04-15 | Franciscus Wilhelmus He Merkus | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin |
| US6794357B1 (en) * | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
| US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| US5830853A (en) | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
| US20010003739A1 (en) * | 1993-06-24 | 2001-06-14 | Astrazeneca Ab | Systemic administration of a therapeutic preparation |
| MY131733A (en) | 1994-12-22 | 2007-08-30 | Astra Ab | Aerosol drug formulations |
| SE9404468D0 (sv) * | 1994-12-22 | 1994-12-22 | Astra Ab | Powder formulations |
| US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| ATE238043T1 (de) * | 1994-12-22 | 2003-05-15 | Astrazeneca Ab | Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation |
| US5955098A (en) * | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
| US7771746B2 (en) * | 1999-12-03 | 2010-08-10 | Polichem Sa | Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| DE60103504T2 (de) * | 2000-01-20 | 2005-06-09 | Basilea Pharmaceutica Ag | Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen |
| US20030008005A1 (en) * | 2001-07-05 | 2003-01-09 | R.T. Alamo Ventures, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
| GB0208742D0 (en) * | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| GB2405334B (en) * | 2002-04-17 | 2006-02-15 | Nektar Therapeutics Uk Ltd | Particulate materials |
| EP2120875B1 (en) * | 2007-02-11 | 2018-07-11 | Map Pharmaceuticals Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
| US20120000941A1 (en) * | 2010-06-30 | 2012-01-05 | Inspire Pharmaceuticals, Inc. | Medicine dispenser |
| WO2017044897A1 (en) | 2015-09-10 | 2017-03-16 | Impel Neuropharma Inc. | In-line nasal delivery device |
| CN110831578A (zh) * | 2017-07-02 | 2020-02-21 | 瑞迪博士实验室有限公司 | 双氢麦角胺的鼻用剂型 |
| KR20200118032A (ko) | 2018-01-05 | 2020-10-14 | 임펠 뉴로파마 인코포레이티드 | 정밀 후각기관 장치에 의한 디하이드로에르고타민의 비강내 전달 |
| WO2020123607A1 (en) | 2018-12-11 | 2020-06-18 | Satsuma Pharmaceuticals, Inc. | Compositions, devices, and methods for treating or preventing headaches |
| GB2581431A (en) * | 2018-12-11 | 2020-08-19 | Satsuma Pharmaceuticals Inc | Compositions, devices, and methods for treating or preventing headaches |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1063512A (en) * | 1962-11-30 | 1967-03-30 | Benger Lab Ltd | Aerosols |
| GB1175430A (en) * | 1966-04-07 | 1969-12-23 | Sandoz Ltd | Pharmaceutical Compositions containing Ergot Alkaloids |
| CH507249A (de) * | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| CH534683A (de) * | 1970-05-26 | 1973-03-15 | Sandoz Ag | Verfahren zur Herstellung neuer Mutterkornpeptidalkaloide |
| US4076715A (en) * | 1972-09-26 | 1978-02-28 | Sandoz Ltd. | 13-Bromo lysergic acid compounds |
| CA990287A (en) * | 1972-09-26 | 1976-06-01 | Sandoz Patents Limited | 13-bromo-lysergic acid compounds |
| NL7314066A (da) * | 1972-10-18 | 1974-04-22 | ||
| US3896228A (en) * | 1973-03-15 | 1975-07-22 | Sandoz Ltd | Method for treating nephrises |
| US3883655A (en) * | 1973-10-11 | 1975-05-13 | Sandoz Ltd | Ergocornine or 2-bromo-{60 -ergocyptine in the treatment of parkinsonism |
| DE2750090A1 (de) * | 1976-11-19 | 1978-06-01 | Sandoz Ag | Neue verabreichungsformen fuer organische verbindungen |
| EP0119493A1 (en) * | 1983-03-16 | 1984-09-26 | American Cyanamid Company | Use of copolymers of 2-acrylamido-2-methylpropane sulfonic acid for improving retention and dewatering in the manufacture of paper |
-
1977
- 1977-11-09 DE DE19772750090 patent/DE2750090A1/de not_active Ceased
- 1977-11-10 NO NO77773839A patent/NO773839L/no unknown
- 1977-11-10 SE SE7712693A patent/SE451944B/sv not_active IP Right Cessation
- 1977-11-10 DK DK499477A patent/DK153440C/da not_active IP Right Cessation
- 1977-11-10 FI FI773376A patent/FI773376A/fi not_active Application Discontinuation
- 1977-11-15 GB GB47437/77A patent/GB1592563A/en not_active Expired
- 1977-11-15 NL NLAANVRAGE7712552,A patent/NL187892C/xx not_active IP Right Cessation
- 1977-11-15 CY CY1266A patent/CY1266A/xx unknown
- 1977-11-16 CA CA290,987A patent/CA1103585A/en not_active Expired
- 1977-11-16 GR GR54819A patent/GR65229B/el unknown
- 1977-11-17 PT PT67292A patent/PT67292B/pt unknown
- 1977-11-17 NZ NZ185711A patent/NZ185711A/xx unknown
- 1977-11-17 HU HU77SA3075A patent/HU185924B/hu unknown
- 1977-11-17 IE IE2345/77A patent/IE46167B1/en not_active IP Right Cessation
- 1977-11-17 FR FR7734591A patent/FR2371454A1/fr active Granted
- 1977-11-17 IL IL7753419A patent/IL53419A/xx unknown
- 1977-11-18 JP JP13803177A patent/JPS5366440A/ja active Granted
- 1977-11-18 AT AT0825477A patent/AT368881B/de active
- 1977-11-18 ES ES464275A patent/ES464275A1/es not_active Expired
- 1977-11-18 CS CS817502A patent/CS228523B2/cs unknown
- 1977-11-18 AU AU30783/77A patent/AU520754B2/en not_active Expired
- 1977-11-18 CS CS777615A patent/CS228502B2/cs unknown
-
1978
- 1978-01-19 DE DE19782802113 patent/DE2802113A1/de not_active Withdrawn
-
1980
- 1980-08-15 PH PH24447A patent/PH23643A/en unknown
-
1981
- 1981-12-08 US US06/328,680 patent/US4462983A/en not_active Expired - Lifetime
-
1984
- 1984-09-01 SG SG617/84A patent/SG61784G/en unknown
- 1984-09-13 KE KE3453A patent/KE3453A/xx unknown
- 1984-11-08 HK HK859/84A patent/HK85984A/xx not_active IP Right Cessation
- 1984-12-30 MY MY55/84A patent/MY8400055A/xx unknown
-
1986
- 1986-06-09 US US06/871,985 patent/US4758423A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO773839L (no) | Fremgangsmaate for fremstilling av ergot-peptid alkaloidpreparatform, egnet for nasal eller pulmonaer tilfoersel | |
| CA2540174C (en) | Aerosol formulation for inhalation, containing an anticholinergic agent | |
| US5603918A (en) | Aerosol composition of a salt of ipratropium and a salt of albuterol | |
| JP2001518494A (ja) | エアゾル投与用の投薬形態 | |
| KR20010075637A (ko) | 포르모테롤을 함유하는 저장 가능한 활성 물질 농축물 | |
| SK279920B6 (sk) | Farmaceutický aerosólový prípravok, zásobník obsah | |
| JPH01153639A (ja) | 鼻又は目に使用する薬剤及びその製造法 | |
| CA2231968A1 (en) | Method of producing a nicotine medicament | |
| HRP20040751A2 (en) | Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect | |
| US20200375945A1 (en) | Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide | |
| SA03240265B1 (ar) | تركيبة حلالة هوائية للاستنشاق تحتوي على مضاد لافراز الكولين | |
| US6193954B1 (en) | Formulations for pulmonary delivery of dopamine agonists | |
| US11304897B2 (en) | Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate | |
| US11642333B2 (en) | Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide | |
| JP2017522293A (ja) | ニコチンの投与計画 | |
| US20050026886A1 (en) | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | |
| JP2018016658A (ja) | 新規噴射剤含有チオトロピウム製剤 | |
| CA2374257A1 (en) | Inhalatory compositions of formoterol | |
| KR20160101928A (ko) | 흡입 약제 | |
| KR820000110B1 (ko) | 맥각 펩티드 알카로이드를 함유하는 약학적 조성물 | |
| JPH0558888A (ja) | 吸入剤 | |
| US20200405700A1 (en) | Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide | |
| RU2098082C1 (ru) | Аэрозольная лекарственная композиция для ингаляций (варианты) | |
| BE860938A (fr) | Nouvelles compositions pharmaceutiques a base d'alcaloide peptidiques de l'ergot de seigle | |
| JPH0558887A (ja) | 吸入剤 |